Literature DB >> 34596680

Reply to letter to the editor by Gupta et al: Bone marrow biopsy in patients with PCNSL: relevant or redundant?

Michelle Margold1, Uwe Schlegel1.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34596680      PMCID： PMC8643433          DOI： 10.1093/neuonc/noab216

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   13.029


× No keyword cloud information.
  4 in total

1.  18F-FDG PET/CT in primary brain lymphoma.

Authors:  Domenico Albano; Giovanni Bosio; Mattia Bertoli; Raffaele Giubbini; Francesco Bertagna
Journal:  J Neurooncol       Date:  2017-11-17       Impact factor: 4.130

2.  Use of FDG-PET/CT for systemic assessment of suspected primary central nervous system lymphoma: a LOC study.

Authors:  Marc Bertaux; Caroline Houillier; Véronique Edeline; Marie-Odile Habert; Karima Mokhtari; Alain Giron; Sébastien Bergeret; Khe Hoang-Xuan; Nathalie Cassoux; Valérie Touitou; Sylvain Choquet; Carole Soussain; Aurélie Kas
Journal:  J Neurooncol       Date:  2020-05-13       Impact factor: 4.130

3.  FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials.

Authors:  Dominic Kaddu-Mulindwa; Bettina Altmann; Viola Poeschel; Dirk Hellwig; Gerhard Held; Stephanie Angel; Stephan Stilgenbauer; Lorenz Thurner; Moritz Bewarder; Maren Schwier; Michael Pfreundschuh; Markus Löffler; Karin Menhart; Jirka Grosse; Marita Ziepert; Ken Herrmann; Ulrich Dührsen; Andreas Hüttmann; Francesco Barbato
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-04-29       Impact factor: 9.236

4.  The value of bone marrow biopsy for staging of patients with primary CNS lymphoma.

Authors:  Michelle Margold; Sabine Seidel; Thomas Kowalski; Swetlana Ladigan-Badura; Alexander Baraniskin; Roland Schroers; Anna Verena Frey; Ingo G H Schmidt-Wolf; Ulrich Herrlinger; Agnieszka Korfel; Uwe Schlegel
Journal:  Neuro Oncol       Date:  2021-12-01       Impact factor: 12.300
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.